These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 39225256)
21. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151 [TBL] [Abstract][Full Text] [Related]
22. Giant gluteal and vesical plexiform neurofibromas in a patient with neurofibromatosis type 1: a case report. Sassi I; Bouida MA; Hasnaoui A; Zemni I; Ben Dhieb T J Med Case Rep; 2024 Jan; 18(1):15. PubMed ID: 38216958 [TBL] [Abstract][Full Text] [Related]
23. Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. Solares I; Viñal D; Morales-Conejo M; Rodriguez-Salas N; Feliu J ESMO Open; 2021 Aug; 6(4):100223. PubMed ID: 34388689 [TBL] [Abstract][Full Text] [Related]
24. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491 [TBL] [Abstract][Full Text] [Related]
25. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage. Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412 [TBL] [Abstract][Full Text] [Related]
26. Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1. Guo YX; Wang HX; Wang SS; Croitoru D; Piguet V; Gao XH; Xu XG JAMA Dermatol; 2024 Mar; 160(3):366-368. PubMed ID: 38198164 [TBL] [Abstract][Full Text] [Related]
27. Treatment for plexiform neurofibromas in patients with NF1. Ardern-Holmes SL; North KN Lancet Oncol; 2012 Dec; 13(12):1175-6. PubMed ID: 23099008 [No Abstract] [Full Text] [Related]
28. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009 [TBL] [Abstract][Full Text] [Related]
29. [Plexiform neurofibroma of the bladder associated with neurofibromatosis type 1: a case report]. Nakazawa S; Yoneda S; Takezawa K; Tanigawa G; Fujita K; Okumi M; Hosomi M; Fukuhara S; Fushimi H; Yamaguchi S Hinyokika Kiyo; 2012 Apr; 58(4):215-8. PubMed ID: 22684263 [TBL] [Abstract][Full Text] [Related]
30. Selumetinib in Children with Inoperable Plexiform Neurofibromas. Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457 [TBL] [Abstract][Full Text] [Related]
31. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019. Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860 [TBL] [Abstract][Full Text] [Related]
32. Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma. Knight T; Shatara M; Carvalho L; Altinok D; Poulik J; Wang ZJ Pediatr Blood Cancer; 2019 Jan; 66(1):e27474. PubMed ID: 30251337 [No Abstract] [Full Text] [Related]
33. Safety and Efficacy of Mek Inhibitors in the Treatment of Plexiform Neurofibromas: A Retrospective Study. Cacchione A; Fabozzi F; Carai A; Colafati GS; Baldo GD; Rossi S; Diana M; Megaro G; Milano GM; Macchiaiolo M; Crocoli A; De Ioris MA; Boccuto L; Secco DE; Zama M; Agolini E; Tomà P; Mastronuzzi A Cancer Control; 2023; 30():10732748221144930. PubMed ID: 36598023 [TBL] [Abstract][Full Text] [Related]
34. Current status of MEK inhibitors in the treatment of plexiform neurofibromas. Gross AM; Dombi E; Widemann BC Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma. Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222 [No Abstract] [Full Text] [Related]
36. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822 [TBL] [Abstract][Full Text] [Related]
37. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC; Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947 [TBL] [Abstract][Full Text] [Related]
38. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi. Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533 [TBL] [Abstract][Full Text] [Related]